Synergistic effect of ponatinib and epigallocatechin-3-gallate induces apoptosis in chronic myeloid leukemia cells through altering expressions of cell cycle regulatory genes

Goker B., Caliskan C., Caglar H. O., Kayabasi C., Balci T., Tepedelen B., ...Daha Fazla

JOURNAL OF BUON, cilt.19, sa.4, ss.992-998, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 4
  • Basım Tarihi: 2014
  • Dergi Adı: JOURNAL OF BUON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.992-998
  • Anahtar Kelimeler: chronic myeloid leukemia, epigallocatechin-3-gallate, ponatinib, tyrosine kinase inhibitors, CHRONIC MYELOGENOUS LEUKEMIA, BCR-ABL, TRANSFORMING GROWTH-FACTOR-BETA-1, PHILADELPHIA-CHROMOSOME, KINASE INHIBITOR, DOWN-REGULATION, UP-REGULATION, GROWTH, PROLIFERATION, ARREST
  • Bursa Uludağ Üniversitesi Adresli: Hayır

Özet

Purpose: Ponatinib (P) has been used for the treatment of chronic myeloid leukemia (CML) and it is known that inhibition of BCR-ABL fusion protein by ponatinib induces apoptosis of CML cells. Epigallocatechin-3-gallate (EGCG), which is a poly phenol in green tea, induces apoptosis in different types of cancer cells. The purpose of this study was to determine the cytotoxic and apoptotic effects of ponatinib and EGCG combination in K562 CML cell line. This study also aimed to detect alterations of the expression levels of cell cycle-regulation related genes after ponatinib and EGCG combination in K562 CML cell line.